Patents by Inventor Nicola Bisek

Nicola Bisek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carrier-linked treprostinil prodrugs
    Patent number: 10729778
    Abstract: Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 4, 2020
    Assignee: Ascendis Pharma A/S
    Inventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
  • HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS
    Publication number: 20200222547
    Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.
    Type: Application
    Filed: September 19, 2019
    Publication date: July 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Sebastian STARK, Thomas KNAPPE, Harald RAU, Nicola BISEK, Burkhardt LAUFER, Samuel WEISBROD, Tobias VOIGT, Germaine FUH, Patrick KOENIG, Chingwei Vivian LEE, Daniela BUMBACA YADAV
  • VEGF neutralizing prodrugs for the treatment of ocular conditions
    Patent number: 10519226
    Abstract: The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: December 31, 2019
    Assignee: Ascendis Pharma Opthalmology Division A/S
    Inventors: Harald Rau, Thomas Knappe, Burkhardt Laufer, Romy Reimann, Samuel Weisbrod, Kennett Sprogøe, Nicola Bisek, Sebastian Stark, Tobias Voigt
  • Prodrugs Comprising a Pyroglutamate Linker
    Publication number: 20190216940
    Abstract: The present invention relates to novel prodrugs of primary or secondary amine-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs and the use of prodrugs.
    Type: Application
    Filed: May 25, 2016
    Publication date: July 18, 2019
    Applicants: Ascendis Pharma A/S, Ascendis Pharma Inc.
    Inventors: Harald Rau, Nicola Bisek, Samuel Weisbrod
  • Carrier-Linked Treprostinil Prodrugs
    Publication number: 20190105400
    Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: January 27, 2017
    Publication date: April 11, 2019
    Applicant: Ascendis Pharma A/S
    Inventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogoe, Thomas Wegge, Oliver Keil, Joachim Zettler
  • Protecting Group Comprising a Purification Tag
    Publication number: 20180312582
    Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.
    Type: Application
    Filed: July 3, 2018
    Publication date: November 1, 2018
    Applicant: Ascendis Pharma A/S
    Inventors: Harald Rau, Nicola Bisek, Thomas Knappe, Romy Reimann, Sebastian Stark, Samuel Weisbrod
  • Protecting group comprising a purification tag
    Patent number: 10040850
    Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: August 7, 2018
    Assignee: Ascendis Pharma A/S
    Inventors: Harald Rau, Nicola Bisek, Thomas Knappe, Romy Reimann, Sebastian Stark, Samuel Weisbrod
  • Hydrogel prodrugs
    Patent number: 9855340
    Abstract: The present invention relates to a process for the preparation of a hydrogel and to a hydrogel obtainable by said process. The present invention further relates to a process for the preparation of a hydrogel-spacer conjugate, to a hydrogel-spacer conjugate obtainable by said process, to a process for the preparation of a carrier-linked prodrug and to carrier-linked prodrugs obtainable by said process, in particular to carrier-linked prodrugs that provide for a controlled or sustained release of a drug from a carrier. In addition, the invention relates to the use of the hydrogel for the preparation of a carrier-linked prodrug.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: January 2, 2018
    Assignee: Ascendis Pharma A/S
    Inventors: Harald Rau, Tobias Voigt, Burkhardt Laufer, Nicola Bisek, Franziska Hahn, Thomas Knappe
  • Prodrugs Comprising an Aminoalkyl Glycine Linker
    Publication number: 20170224829
    Abstract: The present invention relates to novel prodrugs of primary or secondary amine- or hydroxyl-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs and the use of said prodrugs.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 10, 2017
    Applicant: Ascendis Pharma A/S
    Inventors: Nicola BISEK, Harald RAU, Felix CLEEMANN, Thomas KNAPPE, Romy REIMANN
  • Carrier-linked treprostinil prodrugs
    Patent number: 9561287
    Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: February 7, 2017
    Assignee: Ascendis Pharma A/S
    Inventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
  • PROTECTING GROUP COMPRISING A PURIFICATION TAG
    Publication number: 20160257739
    Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.
    Type: Application
    Filed: October 7, 2014
    Publication date: September 8, 2016
    Applicant: Ascendis Pharma A/S
    Inventors: Harald Rau, Nicola Bisek, Thomas Knappe, Romy Reimann, Sebastian Stark, Samuel Weisbrod
  • VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions
    Publication number: 20150297740
    Abstract: The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.
    Type: Application
    Filed: October 8, 2013
    Publication date: October 22, 2015
    Inventors: Harald RAU, Thomas KNAPPE, Burkhardt Laufer, Romy REIMANN, Samuel WEISBROD, Kennett SPROGØE, Nicola BISEK, Sebastian STARK, Tobias VOIGT
  • Hydrogel Prodrugs
    Publication number: 20150258205
    Abstract: The present invention relates to a process for the preparation of a hydrogel and to a hydrogel obtainable by said process. The present invention further relates to a process for the preparation of a hydrogel-spacer conjugate, to a hydrogel-spacer conjugate obtainable by said process, to a process for the preparation of a carrier-linked prodrug and to carrier-linked prodrugs obtainable by said process, in particular to carrier-linked prodrugs that provide for a controlled or sustained release of a drug from a carrier. In addition, the invention relates to the use of the hydrogel for the preparation of a carrier-linked prodrug.
    Type: Application
    Filed: October 8, 2013
    Publication date: September 17, 2015
    Inventors: Harald Rau, Tobias Voigt, Burkhardt Laufer, Nicola Bisek, Franziska Hahn, Thomas Knappe
  • Carrier-Linked Treprostinil Prodrugs
    Publication number: 20140296150
    Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: August 10, 2012
    Publication date: October 2, 2014
    Applicant: Ascendis Pharma A/S
    Inventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler